Search results for: 'system on models soc'

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

16 Feb 2021  |  North America  |  Market Research

Smartphone-based Saliva Testing and Self-monitoring of Blood Glucose Driving the Digital POCT Market

Mobility Ecosystem Holds Bold Promise to Expand Patients’ Access to Care

Infographics

×

Smartphone-based devices and associated tools are becoming the ideal next-generation point-of-care testing (POCT) solutions for in vitro diagnostics. The global COVID-19 pandemic has led to frugal innovations in POCT. The World Health Organization (WHO) has endorsed POCT as the topmost research priority in response to the COVID-19 outbreak. Digital...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

The Transformational Health team at Frost & Sullivan provides critical insights into the US clinical chemistry and immunoassay industry, highlighting the recent activities, key growth opportunities, and trends that are shaping the industry. The already dynamic in vitro diagnostics landscape in the United States was affected even more by the recen...

This research service provides critical insights into the impact of COVID-19 on the global in-vitro diagnostics (IVD) industry, highlighting the growth opportunities, market revenue, and technology trends that influence its growth. Its three major segments identify the strategic imperatives of the IVD industry, the impact of COVID-19 on the IVD gro...

The United States spends more than $3 trillion—nearly 18% of GDP—on healthcare, a massive sector. Healthcare value chain participants face dynamic environments that several trends impact, including the rise in the aging population (16.9% in 2020); chronic disease burden; regulatory challenges; integration across the care continuum; migration to val...

The change in reimbursement for diagnostic testing, pressure from PAMA, regulatory trends in Europe, demand for large-scale testing, shift to precision diagnostics, emerging companies, and evolving business models demand assessing portfolio, evaluating competitor strategies, and exploring opportunities for business growth. The competitive nature of...